HeartLung

HeartLung uses AI for early detection of heart disease, lung cancer, osteoporosis, fatty liver, and other fatal conditions. HeartLung received FDA "Breakthrough Designation” for AutoChamber™ AI that detects enlarged cardiac chambers and left ventricular hypertrophy in non-contrast chest CT scans which are invisible to human eyes. HeartLung cleared FDA 510(k) for AutoBMD™ which is the only DEXA-equivalent, CT-based opportunistic osteoporosis screening approved by FDA that is applicable to 25+ million CT scans every year and is reimbursed by Medicare. HeartLung is awaiting approval for AI-CVD™ which includes multiple AI modules including AI-CAC™ (AI-enabled Coronary Artery Calcium Scoring) focusing on opportunistic screening in chest CT scans. For more information, visit www.heartlung.ai and email contact@heartlung.ai.